Drugs / COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz
COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07640308 | Jul 2026 → Jul 2027 expected | COVID-19 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz | “The COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz is a monovalent vaccine for the prevention of severe cases of COVID-19.” NCT07640308 ↗ |
| Modality | Messenger RNA (mRNA) | “formulation containing messenger ribonucleic acid (mRNA) encoding the Spike protein” NCT07640308 ↗ |
| Route | Intramuscular | “single intramuscular dose” NCT07640308 ↗ |